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The importance of hemodynamic considerations 
jn essential hypertension 
Hypertension is a major risk factor for cardiovascular morbidity and mortality. Antihypertensive 
therapy consistently reduces complications from stroke and congestive heart failure, whereas 
beneiits from the treatment of ischemic heart disease events are variable. Several plausible 
explanations, including hemodynamic hypotheses, have been put forth to account for the failure 
of treatment to more favorably influence mortality from ischemic heart disease. The effect of 
hypertension on coronary heart disease is probably much more complex than a simple elevation 
of arterial pressure. Some of ihese complexities include the potential separate risks of high total 
peripheral resistance, hsgh cardiac output, increased myocardial power that reflects pressure 
t&s flow, and several structural and functional vascular changes. These factors may act in 
concert to unfavorably alter the balance between myocardial oxygen supply and demand. 
Several of these factors will be highlighted in an attempt to offer alternative or adjunctive 
pathophyslologic examlnations for the high-risk subgroups of obesity and the failure of 
antihypertensive therapy to normalize the rate of coronary heart disease events. (AM HEART J 
1988;116:594.) 
Brent Egan, MD, and Robert Schmouder, MD Ann Arbor, Mich. 
Epidemiologic data provide evidence that elevated 
arterial blood pressure is associated with a signifi- 
cantly higher incidence of cardiovascular complica- 
tions, including myocardial infarction.‘s2 Pharmaco- 
logic lowering of arterial pressure reduces total 
cardiovascular morbidity and mortality in hyperten- 
sive patients.3-6 Although the overall event rate is 
reduced, specific ischemic cardiac events are not 
consistently prevented.’ Numerous plausible expla- 
nations have been provided by various experts to 
account for this major shortcoming in several treat- 
ment trials (Table I). 
This review focuses predominantly on the poten- 
tial role of both early and late hemodynamic vari- 
ables, including total peripheral (systemic) vascular 
resistance* (TPR) and cardiac output (CO), as well 
as their product, mean arterial (blood) pressure? 
From the Division of Hypertension, University of Michigan Medical 
Center. 
Reprint requests: Brent Egan, MD, Division of Hypertension, University of 
Michigan Medical Center, 3918 Taubman Center, Ann Arbor, MI 48109- 
0356. 
“Total systemic resistance (TSR) in arbitrary units is equivalent to mean 
blood pressure divided by cardiac output (CO). Total peripheral resistance 
(TPR) equals mean arterial pressure minus mean right atria1 pressure 
divided by CO. Since right atrial pressure is generally 0 to 4 mm Hg in most 
.,I I. 
:>-L‘L.L.,; : “,,<<i,, ,Lzz ;, &f; j .--.*1 C--4:-n nC T‘i‘cl‘i ‘.“lrU‘“*. \,I mean srteria! pressure, in 
practice there is little difference between TPR and TSR.8 
tMean arterial pressure (MAP, mm Hg) implies a value derived from 
integration of the area under the directly measured arterial pulse-wave 
form. Mean blood pressure (MBP, mm Hg) implies a calculated value 
derived from noninvasively measure systolic and diastolic blood pres- 
sure. 
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(MAP), on morbidity and mortality from coronary 
heart disease. Although the review is based on a 
wealth of physiologically sound experimental obser- 
vations, some less recognized pathophysiologic con- 
cepts are explored in an attempt to more fully 
account for incompletely explained epidemiologic 
data. The data include not only the failure of 
antihypertensive therapy to normalize the excessive 
incidence of coronary artery disease, but also the 
excessive cardiac risk accompanying borderline 
hypertension and obesity, particularly in younger 
men. 
HEMODYNAMIC CONSIDERATIONS 
Peripheral vascular resistance. Several observations 
suggest the predominant importance of TPR in 
explaining the cardiac complications associated with 
hypertension. First, increased resistance to blood 
flow is the hemodynamic hallmark of hyperten- 
sion.Q*lo This conclusion is based on a continuously 
fixed pressure and constant flow model of circula- 
tion in which MAP = CO x TPR. However, the 
power generator for the cardiovascular system, the 
heart, is pulsatile. In a pulsatile system, the forces 
opposing ventricular ejection of blood are more 
appropriately termed impedance.” Unfortunately, 
the data needed to quantify impedance require 
considerably more sophisticated measurement tech- 
niques than those needed to obtain data for the 
calculation of TPR. Despite the limitations, the 
simpler steady-state pressure-flow paradigm has 
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provided a useful conceptual framework for inter- 
preting innumerable hemodynamic studies and will 
serve as the predominant model in this discussion. 
As noted, in most persons with elevated arterial 
blood pressure, CO is within the normal range, 
whereas calculated resistance in absolute units is 
high. In hypertensive subjects with increased CO, 
which occurs in a substantial proportion of border- 
line hypertensive and obese persons,12* l3 the absolute 
resistance is normal. However, the resistance in 
relative terms is higher at any specsed level of CO 
for those with higher arterial pressure.14 
The importance of this apparently semantic argu- 
ment is highlighted by hemodynamic data from 
studies on predominantly young men conducted in 
Ann Arbor.15 Subjects were divided into two groups 
on the basis of percentage over ideal body weight 
(IBW). One group was <20% over IBW, whereas the 
other (obese) was >20% over IBW. The obese 
subjects were characterized by higher blood pressure 
(BP) and CO but similar values for peripheral 
resistance in comparison to lean participants. Fur- 
thermore, in the overweight men BP was positively 
correlated to CO, but BP was not related to TPR. 
However, in the lean normotensive men, TPR 
decreased appropriately as CO increased so that BP 
remained normaLl These data are consistent with 
previously reported information that CO is elevated 
similarly in overweight normotensive vs both bor- 
derline and overweight mild hypertensive subjects.13 
Therefore the fundamental hemodynamic mecha- 
nism of elevated BP in both the lean borderline 
hypertensive and overweight borderline-mild sub- 
jects is an inappropriately high resistance for the 
prevailing level of blood flow. Additional studies 
performed in our laboratory indicate that an 
increase in vascular a-adrenergic tone is an impor- 
tant factor in the relatively high resistance to blood 
flow in overweight people.16 These studies were 
conducted in young men who, as will be discussed, 
may be the group at greatest relative hemodynamic 
risk from being overweight. 
Second, CO remains essentially unchanged across 
the spectrum of hypertension, from mild to severe 
levels. Consequently, a successive increase in TPR is 
the predominant explanation for the progression of 
hypertension. Therefore one could argue that the 
progressive rise in TPR is an important component 
of the higher cardiovascular complication rate in 
more severely hypertensive patients. 
Third, antihypertensive compounds that initially 
reduce CO, namely, diuretics and P-blockers, have 
not consistently afforded primary prevention 
against coronary events,34 although exceptions have 
been noted.17 These comments are not intended to 
Table I. Seven recommendations for improving the out- 
come of coronary artery disease in hypertensive patients 
Lower BP more 
Treat BP longer 
Reduce BP less 
Multiple risk factor intervention 
Avoid electrolyte imbalances 
Minimize SNS and RAS activity 
Decrease TPR and not CO 
SNS = sympathetic nervous system; RAS = renin-angiotensin system. 
repudiate either the longer-term hemodynamic 
effects of diuretics or b-blockers, which, in fact, 
include reduction of TPR,‘*p ls or the beneficial 
effects of these compounds on stroke rate,6s6 but 
rather to suggest that pharmacologic approaches to 
reducing ischemic heart disease may be more hemo- 
dynamically complex than simply reducing arterial 
pressure. 
Finally, a study of elderly men observed signifi- 
cantly lower cardiovascular mortality in overweight 
compared with lean hypertensive subjects. The low- 
er absolute TPR in overweight hypertensive sub- 
jects was cited as one potential explanation for their 
more favorable cardiovascular outcome.” 
Cardiac factors in determining the cardiovascular 
complication rate. If cardiovascular mortality were 
simply an inverse function of absolute TPR, then 
obese normotensive subjects would have the lowest 
cardiovascular complication rate, which is not the 
case.21.22 However, there is substantial evidence that 
obesity, which is accompanied by lower absolute 
values for TPR at any given level of arterial pres- 
sure, is an independent risk factor for higher rather 
than lower cardiovascular complication rates.23 Fur- 
thermore, borderline hypertension, which is charac- 
terized by relatively normal absolute values for 
TPR,= I3 is associated with a substantial increase in 
cardiovascular complications despite the minimal 
elevation of blood pressure.%, 25 
Hemodynamically, borderline hypertension and 
obesity are both characterized by elevated absolute 
values for CO.26 In other words, at any given level of 
afterload, which is roughly reflected by higher MAP, 
venous return or preload is also higher.n-29 Conse- 
quently, the heart is exposed to the double burden of 
both increased preload (venous return) and after- 
load (arterial pressure).2s 
The double hemodynamic load in overweight 
patients may explain some of the excessive incidence 
of heart disease. In the Framingham Study, persons 
>20% over ideal weight, when compared with sub- 
jects <20 % overweight, were at threefold higher risk 
for subsequent hypertension.30 Moreover, obese sub- 
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Table II. Hemodynamic power in various patient sub- 
groups 
Data = Lean 
mean + SE NT 
Lean 
BHT Obese HT 
No. 236 129 70 39 
Age 25 +- 1 26 & 1 30 i 1 40 c 1 
% >IBW Ok1 4+-l 23 + 1 1.5 f 2 
SAP 118 -+ 1 132 a 1 134 f 12 150 r+_ 13 
DAP 63 k 1 73 +- 1 76 + 1 85 -+ 2 
CO (L/min) 5.6 k 0.1 6.7 f 0.1 6.7 f 0.2 5.8 f 0.1 
Power 74 f 1 101 -e 3 103 * 34 98 zt 3 
Results of ANOVA: > p < 0.05; = p > 0.05 
Age: HT > obese > BHT = NT 
% IBW: Obese > HT > BHT > NT 
SAP: HT > Obese = BHT > NT 
DAP: HT > Obese = BHT > NT 
CO: Obese = BHT > HT = NT 
Power: Obese = BHT = HT > HT 
SAP = systolic arterial pressure, mm Hg; HT = hypertensive; DAF’ = dia- 
stolic arterial pressure, mm Hg; lean <ZO% over IBW, obese ~20% over 
IBW; BHT = borderline hypertensive; ANOVA = analysis of variance: 
power = CO (cm’hnin) X MAP (1333 dyne/m?) x lo-’ joules/dyne 
(cm) = jouleshin. 
jects were at approximately lo-fold higher risk for 
hypertensive cardiovascular disease (HCVD), which 
is defined as left ventricular hypertrophy by either 
chest radiography or electrocardiography. 
Data from the Australian Heart Foundation 
Study attributed as much as 30 % of hypertension in 
men and women between 25 and 64 years of age to 
being overweight.31 However, within the subgroup of 
men less than 45 years old, as much as 60% of 
hypertension was explained by weight. Therefore 
from a hemodynamic viewpoint, overweight younger 
men may be at the greatest relative risk. Conse- 
quently, an analysis of hemodynamic data in this 
high risk subgroup, as will be discussed, may prove 
enlightening. 
The potential importance of cardiac power. As previ- 
ously noted, the incidence of HCVD in overweight 
subjects substantially exceeds that predicted from 
the higher rates of hypertension. Consequently, it is 
possible that in obesity the double cardiac burden of 
both increased preload and afterload offers a more 
satisfactory explanation than pressure levels alone 
for the excessive HCVD. A prerequisite for initial 
examination of this hypothesis is a quantitative 
expression of that dual cardiac load. 
Preload or venous return is reflected quite pre- 
cisely by CO, since over time venous return and CO 
must be equal. Afterload is approximated by higher 
MAP. In the constant pressure-flow model of the 
circulatory system, the power the heart generates to 
overcome its load equals the product of CO and 
MAP.‘l Therefore cardiac power reflects compo- 
nents of both preload and afterload. Cardiac power 
is also a more comprehensive term than the two 
more commonly used measures: stroke work and 
pressure-rate product. Stroke work does not account 
for the frequency (heart rate) of work, whereas 
pressure-rate product does not include stroke vol- 
ume. 
An index of cardiac power was calculated from 
baseline data obtained in supine volunteers who 
participated in hemodynamic studies conducted in 
the Hypertension Division at Ann Arbor. One 
adjustment was made in the constant pressure-flow 
model in the calculations. Since the left ventricle 
generates CO only during systole, calculated mean 
systolic arterial pressure rather than MAP was used 
in the cardiac power calculation. Because left atrial 
pressure data were unavailable, no adjustment was 
made for this variable in the computation. Thus 
cardiac (left ventricular) power32 was determined by 
the product of CO, as measured by indocyanine 
green dye dilution, and mean systolic pressure, 
calculated from systolic and diastolic pressures mea- 
sured directly from a brachial artery catheter. The 
results are summarized in Table II. As shown, 
cardiac power was substantially higher in lean bor- 
derline hypertensive and obese subjects compared 
with lean normotensive persons. In fact, power in 
these two conditions was virtually identical to levels 
calculated in older subjects with established essen- 
tial hypertension. 
Consequently, cardiac power rather than BP may 
serve as a more useful predictor of age-adjusted 
cardiac complications in borderline hypertension 
and obesity. This hypothesis requires confirmation 
but may provide a partial hemodynamic basis for 
the independent contributions of overweight to car- 
diovascular disease. 21 Indirect confirmation for the 
potential use of cardiac power is provided by data 
obtained in children from Muscatine, Iowa.% Chil- 
dren with BP levels in the upper quintile had a 
higher left ventricular mass index compared with 
their cohorts with BP levels in the lowest quintile. 
Within the upper quintile of BP, children with 
higher COs (greater cardiac power) had the highest 
values for left ventricular mass. 
Vascular Factors (structural vascular abnormalltles). 
In the development of hypertension in the spontane- 
ously hypertensive rat, a progression of structural 
vascular changes occurs. In 6- to &week-old sponta- 
neousiy hyperisrlsive rats, capillary rarefaction is 
followed by functional arteriolar rarefaction at 12 to 
14 weeks and finally structural arteriolar rarefaction 
at 16 to 18 weeks.34 Similarly, capillary rarefaction 
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Table Ill. Known and postulated effects of the hyperten- 
sive process on the balance between myocardial oxygen 
supply and demand 
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HR = hem-t rate; DBP = diastolic blood preesure; EDV = ends diastolic 
volume; HTN = hypertension; LVMM = left ventricular muscle mess. 
has been reported in borderline hypertensive 
humans;= evidence for arteriolar rarefaction has 
been observed in established human hypertensives.36 
Interestingly, in borderline hypertensive subjects, 
the degree of rarefaction was not significantly re- 
lated to arterial pressure, but rather was inversely 
related to CO. In other words, borderline hyperten- 
sive patients with the highest CO displayed the 
greatest degree of capillary rarefaction. In contrast, 
elevated BP induces medial hypertrophy, 35 which 
predominantly involves arteries and larger arteri- 
01es.37 
Functional vascular abnormalltles. One of the most 
widely reported and recognized abnormalities of the 
arterial circulation in hypertension is an impaired 
vasodilator response to ischemia.38-40 The reduced 
vasodilator response to 10 minutes of regional is- 
chemia partially reflects structural vascular 
changes.38-40 However, hypertensive vessels may 
maintain higher tone under some conditions, in part 
through decreased sensitivity to hypoxemia or its 
metabolic consequences. 41 Enhanced vasodilator 
responses to both calcium channel blockade42*43 (an 
index of myogenic tone) and a-receptor antago- 
nists&,45 (an index of vascular a-tone) comprise 
other well-documented functional abnormalities of 
hypertensive vessels. Explanations for these func- 
tional abnormalities are numerous, but agreement 
on specific mechanisms is not uniform. A hypothetic 
schematic depicting the causes and effects of vascu- 
lar changes in the development and progression of 
hypertension is shown in Fig. 1. 
potential relationship of the structural and functional 
vascular changes to ischemlc heart disease. Dimin- 
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Fig. 1. Proposed causes and effects of vascular changes 
in hypertension. 
ished coronary vasodilator reserve has been demon- 
strated in the hearts of hypertensive men and 
animals subjected to pressure overload from either 
systemic hypertension or aortic stenosis.@ The 
impaired vasodilator reserve in hypertensive sub- 
jects likely reflects some of the functional and 
structural vascular changes previously noted. More 
specifically, vascular rarefaction and an increased 
wall-lumen ratio (concentric vascular hypertrophy) 
could provide a structural component to the dimin- 
ished flow reserve. Rarefaction, even in the presence 
of normal total coronary flow levels, would increase 
the mean diffusion distance from individual capil- 
laries to adjacent myocardial cells.47 Thus the myo- 
cardial cells at greatest distance from nutrient sup- 
ply would be at increased risk for ischemia. 
Impaired vasodilator responses to ischemia”’ would 
further exacerbate the effects of the structural and 
functional vascular changes. An increased vascular 
wall-lumen ratio,37 although not documented in the 
coronary circulation,@ would accentuate vascular 
responses to all vasoconstrictor stimuli.37, 3s, 4g, 5a In 
other words, when compared with a normal vessel, 
equivalent degrees of smooth muscle contraction in 
a vessel characterized by greater wall thickness in 
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relationship to luminal radius produce greater com- 
promise of the lumen. 3’ Since resistance varies 
inversely with the fourth power of the radius,51 the 
increased wall-lumen ratio would enhance vascular 
resistance responses to all vasoactive compounds.38 
The enhanced vasoconstrictor responsiveness would 
include that reflecting impaired endothelium- 
dependent vasodilation in hypertension.52 More spe- 
cifically, the vasoconstrictor effects of several com- 
pounds, including thrombin, serotonin, and cate- 
cholamines acting as a2-receptor agonists, are par- 
tially counterbalanced by endothelium-dependent 
vasodilation.53-55 
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would compound the adverse effects on myocardial 
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which is accelerated by hypertension. If the struc- 
tural and functional abnormalities interact diaboli- 
cally in the coronary circulation as postulated, then 
one can envision how these factors would, over time, 
produce ischemia-related events, including angina, 
infarction, arrhythmias, and cardiac decompensa- 
tion. The multiple effects of the hypertensive pro- 
cess and the vascular changes in the balance 
between myocardial oxygen supply and demand are 
summarized in Table III. An extensive discussion of 
the separate risks of left ventricular hypertrophy 
exceeds the scope of this discussion, but the topic 
has been succinctly reviewed.56 
CONCLUSION 
The hemodynamic dysregulation that occurs in 
the development and progression of hypertension 
may contribute not only to elevated arterial blood 
pressure, but may also act in concert with the higher 
pressure levels to induce structural and functional 
cardiovascular changes. The anatomic and physio- 
logic cardiovascular changes, which are not fully 
reversed by antihypertensive therapy, provide the 
substrate for subsequent complications. A greater 
understanding of the sequential hemodynamic 
pathophysiology of hypertension may permit the 
development of more effective treatment strategies. 
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